Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb single-arm open-label luspatercept study in lower-risk MDS with ring sideroblast phenotype
2024-515069-33-00Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by GWT-TUD. Primary endpoint: RBC transfusion independence rate by IWG 2018 modified criteria. Started Feb 2022; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-515069-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515069-33-00.